American Society of Hematology Accepts Telo Genomics' Abstract for Presentation at its 2025 Meeting and Exposition
Telo Genomics (OTCQB: TDSGF) announced that the American Society of Hematology (ASH) accepted its abstract for a poster at the 67th ASH Annual Meeting (Dec 6-9, 2025, Orlando).
Dr. Yulia Shifrin will present Telo's telomere-based Minimal Residual Disease (MRD) methodology that pairs MRD assessment with single-cell risk profiling using the TeloView platform. The abstract will be published in a November supplemental issue of Blood, with full details available after November 3, 2025. The company described the approach as a non-invasive liquid biopsy intended to provide actionable relapse-risk information for clinicians.
Management said ASH acceptance underscores progress toward clinical adoption and broader recognition of Telo's diagnostic technology in the precision oncology diagnostics market.
Telo Genomics (OTCQB: TDSGF) ha annunciato che la American Society of Hematology (ASH) ha accettato il suo abstract per un poster alla 67ª ASH Annual Meeting (6-9 dicembre 2025, Orlando).
La Dott.ssa Yulia Shifrin presenterà la metodologia basata sui telomeri di Minimal Residual Disease (MRD) di Telo, che abbina la valutazione MRD a un profiling di rischio a livello di singola cellula utilizzando la piattaforma TeloView. L'abstract sarà pubblicato in un numero supplementare di novembre di , con i dettagli completi disponibili dopo il 3 novembre 2025. L'azienda ha descritto l'approccio come una biopsia liquida non invasiva finalizzata a fornire informazioni praticabili sul rischio di ricaduta ai clinici.
La direzione ha dichiarato che l'accettazione da parte dell'ASH sottolinea i progressi verso l'adozione clinica e un riconoscimento più ampio della tecnologia diagnostica di Telo nel mercato della diagnostica oncologica di precisione.
Telo Genomics (OTCQB: TDSGF) anunció que la American Society of Hematology (ASH) aceptó su resumen para un póster en la 67th ASH Annual Meeting (del 6 al 9 de diciembre de 2025, Orlando).
La Dra. Yulia Shifrin presentará la metodología basada en telómeros de Minimal Residual Disease (MRD) de Telo, que combina la evaluación de MRD con un perfil de riesgo a nivel de célula única utilizando la plataforma TeloView. El resumen será publicado en un número suplementario de noviembre de Blood, con los detalles completos disponibles después del 3 de noviembre de 2025. La empresa describió el enfoque como una biopsia líquida no invasiva destinada a proporcionar información accionable sobre el riesgo de recaída para los clínicos.
La dirección afirmó que la aceptación por parte de ASH subraya los avances hacia la adopción clínica y un reconocimiento más amplio de la tecnología diagnóstica de Telo en el mercado de diagnósticos de oncología de precisión.
Telo Genomics (OTCQB: TDSGF)는 미주혈액학회(ASH)가 포스터를 위한 초록을 67th ASH Annual Meeting에 채택했다고 발표했습니다(2025년 12월 6-9일, 올랜도).
윤샤프린 박사는 Telo의 텔로미어 기반 Minimal Residual Disease(MRD) 방법론을 발표할 예정이며 MRD 평가와 단일세포 위험 프로파일링을 TeloView 플랫폼으로 결합합니다. 초록은 Blood의 11월 부속호에 게재될 예정이며, 2025년 11월 3일 이후에 전체 세부 정보가 제공됩니다. 이 회사는 이 접근법을 임상의에게 실행 가능한 재발 위험 정보를 제공하기 위한 비침습적 액체 생검으로 설명했습니다.
경영진은 ASH의 채택이 임상 적용으로의 진전과 정밀 종양학 진단 시장에서 Telo의 진단 기술에 대한 더 넓은 인식으로 이어질 것이라고 말했습니다.
Telo Genomics (OTCQB: TDSGF) a annoncé que la American Society of Hematology (ASH) a accepté son résumé pour un poster lors de la 67th ASH Annual Meeting (du 6 au 9 décembre 2025 à Orlando).
La docteure Yulia Shifrin présentera la méthodologie basée sur les télomères de la Minimal Residual Disease (MRD) de Telo, qui associe l’évaluation du MRD à un profilage du risque à l’échelle d’une cellule unique à l’aide de la plateforme TeloView. Le résumé sera publié dans un numéro supplémentaire de novembre de Blood, avec tous les détails disponibles après le 3 novembre 2025. L’entreprise décrit cette approche comme une biopsie liquide non invasive destinée à fournir des informations actionnables sur le risque de rechute pour les cliniciens.
La direction a déclaré que l’acceptation par l’ASH souligne les progrès vers l’adoption clinique et une reconnaissance plus large de la technologie diagnostique de Telo sur le marché des diagnostics en oncologie de précision.
Telo Genomics (OTCQB: TDSGF) gab bekannt, dass die American Society of Hematology (ASH) sein Abstract für ein Poster auf dem 67th ASH Annual Meeting akzeptiert hat (6.–9. Dezember 2025, Orlando).
Dr. Yulia Shifrin wird die telomere-basierte Minimal Residual Disease (MRD)-Methodik vorstellen, die MRD-Bewertung mit Einzelzell-Risikoprofiling unter Nutzung der Plattform TeloView kombiniert. Das Abstract wird in einer November-Sonderausgabe von Blood veröffentlicht, mit vollständigen Details nach dem 3. November 2025. Das Unternehmen beschreibt den Ansatz als nicht-invasive Flüssigbiopsie, die darauf abzielt, den Klinikern umsetzbare Informationen zum Relaprisiko zu liefern.
Die Geschäftsführung sagte, die ASH-Akzeptanz unterstreiche den Fortschritt bei der klinischen Einführung und eine breitere Anerkennung der diagnostischen Technologie von Telo im Markt für Präzisions-Onkologie-Diagnostika.
Telo Genomics (OTCQB: TDSGF) أعلنت أن الجمعية الأمريكية لأمراض الدم (ASH) قبلت ملخصها لملصق في الاجتماع السنوي الـ67 لـ ASH (6-9 ديسمبر 2025، أورلاندو).
ستقدم الدكتورة يويا شيفرين منهجية Minimal Residual Disease (MRD) القائمة على التيلومرات من Telo والتي تقابل تقييم MRD بنمط ملفّات المخاطر عند مستوى خلية واحدة باستخدام منصة TeloView. سيُنشر الملخص في عدد إضافي من نوفمبر من Blood، مع توفر التفاصيل الكاملة بعد 3 نوفمبر 2025. وصفت الشركة النهج بأنه فحص سائل غير جراحي يهدف إلى تزويد الأطباء بمعلومات قابلة للاستخدام عن مخاطر الانتكاس.
وقالت الإدارة إن قبول ASH يبرز التقدم نحو الاعتماد السريري والاعتراف الأوسع بتقنية تشخيص Telo في سوق تشخيصات الأورام الدقيقة.
Telo Genomics (OTCQB: TDSGF) 宣布，美国血液学会（ASH）已接受其用于海报的摘要，参加在67th ASH Annual Meeting（2025年12月6-9日，奥兰多）举行的会议。
Yulia Shifrin 博士将展示基于端粒的 Minimal Residual Disease (MRD) 方法学，该方法将 MRD 评估与使用 TeloView 平台的单细胞风险分析相结合。该摘要将刊登在 Blood 的 11 月增刊中，完整细节将于 2025 年 11 月 3 日之后提供。公司将该方法描述为非侵入性的液体活检，旨在为临床医生提供可操作的复发风险信息。
管理层表示，ASH 的接纳强调了向临床应用的进展以及 Telo 的诊断技术在精准肿瘤诊断市场中获得更广泛认可。
- None.
- None.
Recognition highlights commercial potential of Telo's telomere-based MRD technology in the growing precision oncology market
Toronto, Ontario--(Newsfile Corp. - October 9, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through its proprietary multi-factor analysis of telomeres, today announced that the American Society of Hematology ("ASH") has accepted Telo Genomics' abstract submission for a poster presentation during the upcoming 2025 Annual Meeting.
Dr. Yulia Shifrin, Laboratory Director of Telo Genomics, will present the abstract. The contents of the abstract will also be published online in a November supplemental issue of Blood. The abstract entails Telo's Minimal Residual Disease ("MRD") clinical methodology, which combines MRD assessment with risk profiling of individual cancer cells based on the TeloView® platform. Telo's proprietary approach to MRD is based on a non-invasive liquid biopsy and has the potential to provide best-in-class actionable information on the risk of relapse to clinicians.
Details of the abstract will be available after November 3, 2025.
The American Society of Hematology (ASH) is the world's largest professional society of clinicians and scientists dedicated to advancing the understanding, diagnosis, treatment, and prevention of blood disorders. It's upcoming 67th ASH Annual Meeting and Exposition will take place December 6-9, 2025, in Orlando, Florida.
"Acceptance at ASH 2025 represents an important acknowledgement of our technology and continued progress toward clinical adoption," said Dr. Sabine Mai, Telo's Co-Founder. "Showcasing our MRD platform at one of the most prestigious global hematology meetings highlights the growing recognition of Telo's innovation and reinforces our commitment to building long-term value and establishing a differentiated position in a growing multi-billion-dollar diagnostics market."
About MRD Assessment
Minimal Residual Disease ("MRD") is defined as the small number of cancer cells that remain in the body after treatment, stratifying MRD cells, between being in remission or active, provides important actionable information for clinicians. Also, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted unanimously in April 2024 to accept MRD as a clinical endpoint for accelerated approval of new multiple myeloma therapies, paving the way for faster drug approvals in multiple myeloma.
MRD testing is emerging as a valuable tool in assessing treatment response and guiding therapeutic decisions in oncology. With advancements in drug development technologies, and a growing emphasis on personalized healthcare, the MRD testing industry is expected to exhibit substantial global expansion in the coming years. The MRD global testing market size is expected to reach USD 4.1 billion by 2032 (Globe Newswire - August 14, 2023).
About Multiple Myeloma
Multiple myeloma is a challenging and potentially deadly blood cancer that involves plasma cells, a type of blood cell that helps to fight infection. It is the second most common blood cancer with an incidence of 35,000 new cases every year in the US, and ~180,000 patients receiving treatment at any given time. The introduction of next-generation therapies (including targeted treatments) has increased the median survival rate to over 5 years, but MM is still considered incurable. Two asymptomatic precursors, Monoclonal Gammopathy of Unknown Significance ("MGUS") and SMM generally precede the progression to classic symptomatic MM. While MGUS carries a steady risk of progression of
About Telo Genomics
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information, please visit www.telodx.com.
For further information, please contact:
Brett Maas
Managing Partner
(646) 536-7331
Brett@HaydenIR.com
7320 E. Butherus Drive
Scottsdale, AZ 85260
haydenir.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Certain forward-looking statements, including statements regarding the Company's receipt of TSXV acceptance of the stock option grant are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/269754
FAQ
What did Telo Genomics (TDSGF) announce about ASH 2025?
Who will present Telo Genomics' abstract at ASH 2025 for TDSGF?
What does the Telo Genomics (TDSGF) abstract describe?
When will full details of Telo Genomics' ASH abstract be available?
How might Telo Genomics' MRD platform affect clinicians?
Where and when is the ASH 2025 meeting Telo Genomics will attend?
